Ausgabe 4/2021
Inhalt (10 Artikel)
Editorial
Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment
R. Brett McQueen, Julia F. Slejko
Open Access
Review Article
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
Simone A. Huygens, Matthijs M. Versteegh, Stefan Vegter, L. Jan Schouten, Tim A. Kanters
Systematic Review
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review
Anindit Chhibber, Alexandre Hikiji Watanabe, Chayutthaphong Chaisai, Sajesh K. Veettil, Nathorn Chaiyakunapruk
Original Research Article
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States
Anita J. Brogan, Sandra E. Talbird, Ashley E. Davis, Elizabeth M. La, Princy N. Kumar
Open Access
Original Research Article
Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success
Björn Schwander, Mark Nuijten, Silvia Evers, Mickaël Hiligsmann
Original Research Article
Macrovascular Risk Equations Based on the CANVAS Program
Michael Willis, Christian Asseburg, April Slee, Andreas Nilsson, Cheryl Neslusan
Open Access
Original Research Article
EQ-5D-Y Value Set for Slovenia
Valentina Prevolnik Rupel, Marko Ogorevc, Wolfgang Greiner, Simone Kreimeier, Kristina Ludwig, Juan Manuel Ramos-Goni
Open Access
Letter to the Editor
Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
Kelly Hollenack, Jade Marshall
Letter to the Editor
Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
Edward E. Neuberger, Josh J. Carlson, David L. Veenstra
Letter to the Editor
The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases
Jesse Elliott, George A. Wells, Doug Coyle